Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena?

Authors Ajoy Kumar, Vibhuti Singh

Published Date July 2010 Volume 2010:6 Pages 665—669

DOI http://dx.doi.org/10.2147/VHRM.S5686

Published 30 July 2010

Ajoy Kumar1, Vibhuti Singh2

1Bayfront Family Medicine Residency, St Petersburg FL, USA; 2University of South Florida College of Medicine and Suncoast Cardiovascular Center, St Petersburg, FL, USA

Abstract: When compared with the general population, the diabetic population is at higher risk of cardiovascular disease (CVD), as predicted by the Framingham Risk Score calculations (10-year risk 20%). For this reason diabetes is considered a “coronary disease equivalent” condition, as classified by the National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III. Furthermore, patients with diabetes who experience a myocar­dial infarction have a poorer prognosis than non­diabetic patients, which contributes to their overall higher mortality. Dyslipidemia is a major underlying risk factor contributing to the excess CVD risk, and is usually more atherogenic in the presence of diabetes. It is uniquely manifested by raised levels of triglycer­ides, low levels of high-density lipoprotein cholesterol, and smaller, denser, and more atherogenic low-density lipoprotein particles. Recent trials have suggested the need for more aggressive treatment of dyslipidemia in this subpopulation than the current recommendations by the NCEP-ATP III. This review addresses the newer developments in the diabetes arena in terms of our current understanding of atherogenic dyslipidemia in diabetes and data from the latest randomized trials addressing its management.

Keywords: atherogenic dyslipidemia, diabetes mellitus

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry

Schaefer JR, Gitt AK, Sonntag F, Weizel A, Jannowitz C, Karmann B, Pittrow D, Bestehorn K

Vascular Health and Risk Management 2013, 9:71-80

Published Date: 21 February 2013

Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer

Chauhan A, Zubair S, Tufail S, Sherwani A, Sajid M, Raman SC, Azam A, Owais M

International Journal of Nanomedicine 2011, 6:2305-2319

Published Date: 12 October 2011

Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease

Stricker RB, DeLong AK, Green CL, Savely VR, Chamallas SN, Johnson L

International Journal of General Medicine 2011, 4:639-646

Published Date: 6 September 2011

Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease

Mannu P, Rinaldi S, Fontani V, Castagna A

Clinical Interventions in Aging 2011, 6:207-211

Published Date: 26 July 2011

Pre-eclampsia: pathophysiology, diagnosis, and management

Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi J-M

Vascular Health and Risk Management 2011, 7:467-474

Published Date: 19 July 2011

Low high-density lipoprotein cholesterol: current status and future strategies for management

Vibhuti Singh, Rakesh Sharma, Ajoy Kumar, et al

Vascular Health and Risk Management 2010, 6:979-996

Published Date: 29 October 2010

Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies

Christina Voulgari, Dimitrios Papadogiannis, Nicholas Tentolouris

Vascular Health and Risk Management 2010, 6:883-903

Published Date: 11 October 2010

Benefits of statin therapy and compliance in high risk cardiovascular patients

Joel A Lardizabal, Prakash C Deedwania

Vascular Health and Risk Management 2010, 6:843-853

Published Date: 23 September 2010

Randomized study to compare valsartan ± HCTZ versus amlodipine ± HCTZ strategies to maximize blood pressure control

Dion Zappe, Cheraz Cherif Papst, Philippe Ferber, et al.

Vascular Health and Risk Management 2009, 5:883-892

Published Date: 22 October 2009

Alogliptin: a new addition to the class of DPP-4 inhibitors

Radha Andukuri, Andjela Drincic, Marc Rendell

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:117-126

Published Date: 21 July 2009